Alnylam Pharmaceuticals and Tenaya Therapeutics struck a research collaboration in which Tenaya will deliver up to 15 novel genetic targets for cardiovascular disease discovery. Alnylam committed $10 million upfront with potential milestone payments that could total roughly $1.13 billion if targets translate to approved therapies. The deal pairs Tenaya’s gene‑target discovery platform with Alnylam’s RNAi drug development and commercialization capabilities. Tenaya retains its internal gene‑therapy programs while the partnership validates its target discovery engine and signals sustained pharma appetite for genetics‑driven cardiovascular innovation.